Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wouter Hoefsloot

Showing results (11-20 of 79) with videos related to

Pageof 8
Sort By:
International Journal of Antimicrobial Agents|May 14, 2013
Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significanceJakko van Ingen, Wouter Hoefsloot, Johan W Mouton, et al.
Respiratory Medicine|September 27, 2017
Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohortSanne Zweijpfenning, Stephan Kops, Cecile Magis-Escurra, et al.
Respiratory Investigation|August 2, 2025
The spectrum of CFTR dysfunction in patients with nontuberculous mycobacterial pulmonary diseaseArthur Lemson, Monique Reijers, Dineke Westra, et al.
Journal of Bronchology & Interventional Pulmonology|July 11, 2020
Cone-Beam CT Image Guidance With and Without Electromagnetic Navigation Bronchoscopy for Biopsy of Peripheral Pulmonary LesionsRoel L J Verhoeven, Jurgen J Fütterer, Wouter Hoefsloot, et al.
The Journal of Antimicrobial Chemotherapy|November 10, 2025
Enhanced antimycobacterial efficacy of simulated inhaled clofazimine versus oral clofazimine in combination with azithromycin and ethambutol in a hollow-fiber systemJelmer Raaijmakers, Rob Aarnoutse, Lindsey Te Brake, et al.
Antimicrobial Agents and Chemotherapy|October 25, 2023
The role of rifampicin within the treatment of <i>Mycobacterium avium</i> pulmonary diseaseJodie A Schildkraut, Jelmer Raaijmakers, Rob Aarnoutse, et al.
Journal of Clinical Microbiology|February 15, 2019
Implementation of Semiautomated Antimicrobial Susceptibility Interpretation Hardware for Nontuberculous Mycobacteria May Overestimate SusceptibilityMariëlle Rockland, Mike Marvin Ruth, Nicole Aalders, et al.
Expert Review of Respiratory Medicine|October 3, 2017
Pulmonary disease by non-tuberculous mycobacteria - clinical management, unmet needs and future perspectivesLars-Olof Larsson, Eva Polverino, Wouter Hoefsloot, et al.
Expert Review of Respiratory Medicine|March 21, 2025
Treatment of nontuberculous mycobacterial pulmonary disease requires a stepwise and multidisciplinary approachArthur Lemson, Arjan van Laarhoven, Lisa Kurver, et al.
Respiratory Research|April 8, 2015
High definition bronchoscopy: a randomized exploratory study of diagnostic value compared to standard white light bronchoscopy and autofluorescence bronchoscopyErik H F M van der Heijden, Wouter Hoefsloot, Hieronymus W H van Hees, et al.
Pageof 8

Showing results (11-20 of 79) with videos related to

Sort By:
Pageof 8
International Journal of Antimicrobial Agents|May 14, 2013
Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significanceJakko van Ingen, Wouter Hoefsloot, Johan W Mouton, et al.
Respiratory Medicine|September 27, 2017
Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohortSanne Zweijpfenning, Stephan Kops, Cecile Magis-Escurra, et al.
Respiratory Investigation|August 2, 2025
The spectrum of CFTR dysfunction in patients with nontuberculous mycobacterial pulmonary diseaseArthur Lemson, Monique Reijers, Dineke Westra, et al.
Journal of Bronchology & Interventional Pulmonology|July 11, 2020
Cone-Beam CT Image Guidance With and Without Electromagnetic Navigation Bronchoscopy for Biopsy of Peripheral Pulmonary LesionsRoel L J Verhoeven, Jurgen J Fütterer, Wouter Hoefsloot, et al.
The Journal of Antimicrobial Chemotherapy|November 10, 2025
Enhanced antimycobacterial efficacy of simulated inhaled clofazimine versus oral clofazimine in combination with azithromycin and ethambutol in a hollow-fiber systemJelmer Raaijmakers, Rob Aarnoutse, Lindsey Te Brake, et al.
Antimicrobial Agents and Chemotherapy|October 25, 2023
The role of rifampicin within the treatment of <i>Mycobacterium avium</i> pulmonary diseaseJodie A Schildkraut, Jelmer Raaijmakers, Rob Aarnoutse, et al.
Journal of Clinical Microbiology|February 15, 2019
Implementation of Semiautomated Antimicrobial Susceptibility Interpretation Hardware for Nontuberculous Mycobacteria May Overestimate SusceptibilityMariëlle Rockland, Mike Marvin Ruth, Nicole Aalders, et al.
Expert Review of Respiratory Medicine|October 3, 2017
Pulmonary disease by non-tuberculous mycobacteria - clinical management, unmet needs and future perspectivesLars-Olof Larsson, Eva Polverino, Wouter Hoefsloot, et al.
Expert Review of Respiratory Medicine|March 21, 2025
Treatment of nontuberculous mycobacterial pulmonary disease requires a stepwise and multidisciplinary approachArthur Lemson, Arjan van Laarhoven, Lisa Kurver, et al.
Respiratory Research|April 8, 2015
High definition bronchoscopy: a randomized exploratory study of diagnostic value compared to standard white light bronchoscopy and autofluorescence bronchoscopyErik H F M van der Heijden, Wouter Hoefsloot, Hieronymus W H van Hees, et al.
Pageof 8